The strong PFS data and compelling crossover survival signal support a viable BLA path despite the OS miss; traders should monitor the upcoming FDA meeting for feedback on accelerated approval potential. A positive readout could trigger significant upside given the high unmet need and lack of competition in second-line BTC.
Price Chart
Executive Summary
Compass Therapeutics announced that tovecimig, in combination with paclitaxel, achieved a highly statistically significant improvement in progression-free survival (PFS) in the COMPANION-002 trial for second-line biliary tract cancer, with median PFS of 4.7 months vs. 2.6 months (HR=0.44, p<0.0001). While overall survival (OS) did not meet statistical significance due to high crossover (54%), post hoc analyses showed crossover patients had markedly improved OS (12.8 vs. 6.1 months). The company plans to meet with the FDA ahead of a Biologics License Application (BLA) submission.
Key Facts
- Tovecimig + paclitaxel improved median PFS to 4.7 months vs. 2.6 months for paclitaxel alone (HR=0.44, p<0.0001), a 56% reduction in progression risk.
- OS did not reach statistical significance due to 54% crossover from control arm to tovecimig, confounding the analysis.
- Post hoc analysis showed crossover patients had median OS of 12.8 months vs. 6.1 months for non-crossover patients (HR=0.54, p=0.04).
- Primary endpoint of ORR was previously met: 17.1% vs. 5.3% (p=0.031).
- 85% of all study patients received tovecimig, with a pooled median OS of 8.9 months, above historical benchmarks of ~6 months.
- Safety profile was consistent with prior data; most common Grade ≥3 AEs were hypertension (44%) and neutropenia (36%).
- No FDA-approved therapy exists for second-line BTC without actionable mutations, creating significant unmet need.
Financial Impact
Potential blockbuster opportunity in a rare cancer with no approved second-line therapy; peak sales estimates could exceed $500M annually if approved.
Risk Factors
- FDA may require additional data or a confirmatory trial before granting approval, especially given the OS non-significance.
- High crossover complicates interpretation of OS, which could be a point of contention during regulatory review.
- Competition may emerge from other late-stage targeted therapies or immunotherapies in BTC.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281512 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 3d ago | Press Release | $0.7472 | awaiting T+20 | — | $0.7470 (−0.03%) |
Sep 22, 2026 5w ago | 8-K | $1.24 $0.8330 | ▲ +32.82% | ▲ +32.26% | $0.7470 (+39.76%) |
Aug 21, 2026 9w ago | Institutional Cluster | $2.40 $1.90 | ▼ −20.83% | ▼ −20.55% | $0.7470 (−68.88%) |
Aug 6, 2026 11w ago | 8-K | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7470 (−62.46%) |
Aug 6, 2026 11w ago | Press Release | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7470 (−62.46%) |
Jul 17, 2026 14w ago | Press Release | $2.05 $2.25 | ▲ +9.76% | ▲ +5.31% | $0.7470 (−63.56%) |
Jul 1, 2026 16w ago | 8-K | $2.27 $1.94 | ▼ −14.54% | ▼ −14.12% | $0.7470 (−67.09%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.03 $2.33 | ▲ +14.78% | ▲ +13.00% | $0.7470 (−63.20%) |
May 21, 2026 22w ago | Press Release | $2.07 $2.09 | ▲ +0.72% | ▲ +2.14% | $0.7470 (−63.91%) |
May 5, 2026 25w ago | 8-K | $1.95 $2.08 | ▲ +6.67% | ▲ +1.71% | $0.7470 (−61.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers